List of Excipients in Branded Drug RILUTEK

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Covis Pharma US Inc	RILUTEK	riluzole	70515-700	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
Covis Pharma US Inc	RILUTEK	riluzole	70515-700	CELLULOSE, MICROCRYSTALLINE
Covis Pharma US Inc	RILUTEK	riluzole	70515-700	CROSCARMELLOSE SODIUM
Covis Pharma US Inc	RILUTEK	riluzole	70515-700	HYPROMELLOSE
Covis Pharma US Inc	RILUTEK	riluzole	70515-700	MAGNESIUM STEARATE

Rilutek Excipient Strategy and Commercial Opportunities

Last updated: August 26, 2026

Rilutek is the original riluzole 50 mg film-coated tablet approved for amyotrophic lateral sclerosis. Its core commercial opportunity is no longer molecule exclusivity. It is dosage-form differentiation, particularly for patients with dysphagia, feeding-tube requirements, swallowing difficulty, and adherence problems. The highest-value excipient strategies are liquid suspension, taste masking, rapid disintegration, dose uniformity, and food-effect control.

What is Rilutek and how is it administered?

Rilutek contains riluzole, a benzothiazole compound used to extend survival or time to tracheostomy in patients with ALS. The approved tablet strength is 50 mg, generally administered twice daily at least one hour before or two hours after meals because food reduces riluzole exposure.[1]

Product	Active ingredient	Dosage form	Strength	FDA status
Rilutek	Riluzole	Film-coated tablet	50 mg	Original NDA 020599, approved 1995
Tiglutik	Riluzole	Oral suspension	350 mg/7 mL	FDA-approved liquid product
Exservan	Riluzole	Oral film	50 mg	FDA-approved oral film
Generic riluzole	Riluzole	Primarily tablet; other forms may be available	50 mg	Approved through ANDA pathway

The original Rilutek presentation uses a conventional immediate-release tablet platform. The label identifies inactive ingredients including microcrystalline cellulose, hypromellose, magnesium stearate, colloidal silicon dioxide and sodium starch glycolate, with film-coating components.[1]

What excipients are used in Rilutek tablets?

The Rilutek tablet is built around standard immediate-release excipient functions:

Excipient function	Likely Rilutek formulation role
Diluent and compression aid	Microcrystalline cellulose
Disintegrant	Sodium starch glycolate
Glidant	Colloidal silicon dioxide
Lubricant	Magnesium stearate
Film former	Hypromellose
Coating aid or plasticizer	Polyethylene glycol and related coating components
Opacifier or colorant	Titanium dioxide, where applicable

The formulation is commercially efficient because it uses well-established excipients with broad regulatory histories. That reduces manufacturing complexity and supports generic tablet development. It also leaves limited room for premium pricing unless a new presentation solves a clinical or operational problem.

The main technical constraints are riluzole’s poor aqueous solubility, food-sensitive absorption, bitter taste and the need to maintain dose uniformity at a relatively low tablet mass.

What excipient strategies can improve Rilutek formulations?

Taste-masked oral suspension

A liquid riluzole product requires more than simply dispersing the drug in water. A commercial suspension needs:

• A suspending polymer such as xanthan gum, hypromellose or a structured cellulose system.
• A wetting agent to improve dispersion of hydrophobic drug particles.
• Buffer control to maintain chemical stability.
• Sweetener and flavor system to reduce bitterness.
• Preservative protection for a multidose bottle.
• Redispersibility after storage.
• Accurate dosing through an oral syringe.

Tiglutik demonstrates that liquid riluzole has regulatory and commercial value, particularly for patients who cannot swallow tablets.[2] The opportunity for follow-on products is a lower-cost generic suspension, a more palatable formulation, a smaller package, or a ready-to-administer presentation.

The principal development risks are sedimentation, caking, particle-size drift, preservative compatibility and dose nonuniformity. A suspension that requires vigorous shaking or produces inconsistent syringe doses creates a practical barrier in home use and long-term care settings.

Oral film and fast-dissolving systems

Exservan uses an oral film approach for patients with swallowing difficulty.[3] Film systems can eliminate the need for water and reduce pill burden. Suitable excipient categories include:

• Film-forming polymers such as pullulan, hypromellose or maltodextrin.
• Plasticizers such as polyethylene glycol or glycerol.
• Solubilizers and wetting agents.
• Sweeteners, flavors and bitterness suppressants.
• Permeation and saliva-wetting aids.

The commercial challenge is dose loading. A 50 mg riluzole dose is substantial for a thin oral film, so uniformity, tensile strength, disintegration time and mouthfeel become critical. The product must also protect against moisture uptake and brittleness during packaging and storage.

Rapid-disintegrating tablets

A conventional tablet could be repositioned as an orally disintegrating tablet using a combination of:

• Crospovidone, croscarmellose sodium or sodium starch glycolate.
• Mannitol or spray-dried mannitol for mouthfeel.
• Low-level surfactant to improve wetting.
• Taste-masking polymer or coated riluzole particles.
• Direct-compression excipients with adequate tablet strength.

This strategy may provide a lower-cost alternative to oral film. The commercial value depends on achieving acceptable taste without excessive coating or granulation costs.

Multiparticulates and sprinkle formulations

Multiparticulate beads or granules could support administration through soft food or selected feeding tubes. Excipient options include polymeric coatings, pelletization binders, anti-tacking agents and protective overcoats.

The regulatory and clinical value would depend on demonstrating:

• Consistent dose delivery.
• No meaningful food-related exposure distortion beyond the approved label conditions.
• Compatibility with feeding tubes.
• Adequate stability after opening or dispersion.
• No hazardous aerosolization or occupational exposure during handling.

This is a technically attractive but more complex route than a standard tablet or suspension.

What commercial opportunities exist for Rilutek excipients?

Which patient segments create the strongest opportunity?

The strongest opportunity is the ALS population with impaired swallowing. ALS commonly produces progressive bulbar dysfunction, which can make tablets difficult to administer. Caregivers, home nurses and long-term care facilities also value accurate liquid dosing and reduced manipulation.

Commercial targets include:

1. Patients unable to swallow conventional tablets.
2. Patients using enteral feeding tubes.
3. Patients with adherence problems caused by pill burden.
4. Home-care and hospice settings requiring easy administration.
5. Pharmacies seeking lower-cost alternatives to branded liquid or film products.

A generic 50 mg tablet competes primarily on price. A liquid, film or tube-compatible product can compete on administration value.

How can excipients support premium pricing?

Excipient-driven differentiation can support higher pricing when it produces a measurable advantage:

Differentiation	Commercial value
Better taste masking	Higher acceptance and fewer administration failures
No-water oral film	Easier use outside clinical settings
Low-sedimentation suspension	More reliable dosing
Smaller dose volume	Improved caregiver usability
Feeding-tube compatibility	Access to patients unable to swallow
Longer in-use stability	Lower pharmacy and caregiver waste
Single-dose packaging	Better hygiene and dose accuracy
Moisture-resistant film packaging	Longer shelf life and fewer defects

The strongest premium proposition is not a novel excipient alone. It is a complete administration system that reduces caregiver burden and improves dose reliability.

What patent protection covers Rilutek and its formulations?

Riluzole’s original active-ingredient patent protection has expired in the United States. The principal intellectual-property value now lies in later product-specific patents, formulation claims, manufacturing processes, device components and regulatory exclusivity associated with liquid or oral-film products.

What patents protect Rilutek tablets?

The original Rilutek tablet was protected primarily through riluzole compound and pharmaceutical-composition rights. Those rights do not provide a current barrier to ordinary generic riluzole tablets. Generic manufacturers can generally rely on the abbreviated new drug application pathway if they satisfy bioequivalence and labeling requirements.

What formulation patents may affect oral liquids and films?

Potentially relevant claim categories include:

• Riluzole particle-size distributions.
• Stabilized aqueous suspensions.
• Taste-masked riluzole compositions.
• Oral films with defined polymer ratios.
• Packaging systems that preserve moisture sensitivity.
• Feeding-tube administration methods.
• Manufacturing methods that improve content uniformity.

A formulation patent is commercially meaningful only if its claims cover the product’s actual composition or manufacturing process and survive validity and infringement review. Excipients listed in a patent are not, by themselves, evidence of market exclusivity.

When does Rilutek lose exclusivity?

Rilutek’s original small-molecule and tablet exclusivity has expired. Current market protection depends on product-specific patents, any remaining regulatory exclusivity for later presentations, trademarks, supply contracts and physician or caregiver familiarity.

Rilutek is not a biologic, so biosimilar risk is not relevant. The competitive threat comes from generic riluzole tablets and alternative branded riluzole dosage forms.

What is the FDA regulatory status of Rilutek and competing riluzole products?

Rilutek was approved under a conventional NDA. Generic tablets use the 505(j) ANDA pathway. A materially different dosage form, such as a suspension or oral film, generally requires a separate NDA or a suitable regulatory pathway supported by product-specific safety, quality and bioequivalence data.

The principal FDA issues for excipient-led development are:

• Acceptability of the inactive ingredients under the FDA Inactive Ingredient Database.
• Comparative bioavailability and food-effect performance.
• Dose uniformity in liquids and films.
• Stability after opening.
• Preservative effectiveness for multidose liquids.
• Compatibility with dosing devices and feeding tubes.
• Labeling for administration relative to meals.

An excipient change to a conventional generic tablet may fit a postapproval change framework. A new commercial presentation that changes route, dissolution behavior or administration method will face a higher regulatory burden.

How strong is the Rilutek patent estate?

The original Rilutek tablet estate is weak as a barrier to generic tablet entry because the relevant compound and basic product rights are mature. The estate is stronger for differentiated presentations when claims cover a specific suspension, film matrix, taste-masking process, stability profile or delivery device.

Asset type	Barrier to generic tablets	Barrier to alternative dosage forms
Original riluzole compound claims	Low	Low
Basic 50 mg tablet formulation	Low	Low
Suspension composition	Low	Moderate to high, if claims are narrow and valid
Oral film composition	Low	Moderate to high
Taste-masking process	Low	Moderate
Feeding-tube method	Low	Moderate
Device and packaging claims	Low	Moderate

Patent risk should be analyzed product by product. A tablet manufacturer is unlikely to face the same barriers as a suspension or oral-film developer.

Which companies are challenging the Rilutek market?

The principal competitive groups are:

• Generic riluzole manufacturers selling 50 mg tablets.
• Branded specialty companies selling liquid or oral-film riluzole.
• Contract manufacturers with oral-liquid and oral-film platforms.
• Excipient suppliers offering taste-masking, suspension and film technologies.
• Specialty pharmacies and distributors serving ALS patients.

The generic tablet market is likely to remain price competitive. The higher-margin opportunity is differentiated administration, where manufacturing capability, clinical usability and distribution access matter more than the active ingredient.

What generic launch scenarios exist for Rilutek?

Low-cost tablet launch

This is the lowest-risk scenario. A manufacturer uses a conventional immediate-release formulation with standard excipients. The main risks are price erosion, established generic competition and limited differentiation.

Generic oral suspension

This offers greater commercial separation but requires control of sedimentation, taste, microbiological quality and dosing accuracy. The product can compete with branded liquid riluzole if it achieves reliable administration at a lower price.

Generic oral film

This has a stronger convenience proposition but carries higher technical risk. Film manufacture, dose uniformity, packaging and taste masking can materially increase cost.

Tube-compatible granule or suspension

This targets a narrower population but may generate defensible clinical utility. The value depends on validated administration data and distribution through ALS-focused channels.

What licensing opportunities exist in Rilutek excipients?

Licensing opportunities are more likely to involve platform technology than the riluzole molecule. Relevant assets include:

• Taste-masking systems for bitter hydrophobic drugs.
• Ready-to-use suspension platforms.
• Oral-film manufacturing technology.
• Moisture-barrier packaging.
• Feeding-tube delivery systems.
• Device technologies that improve liquid dose accuracy.

A deal structure could combine a formulation patent, development services, commercial manufacturing and milestone payments. The most attractive partner would have both regulatory experience with 505(b)(2) or ANDA products and access to neurology or ALS distribution.

Key Takeaways

• Rilutek is a mature riluzole tablet product with limited remaining value from basic tablet exclusivity.
• Excipient strategy is commercially relevant because ALS patients often have swallowing and administration problems.
• The strongest opportunities are suspension, oral film, taste-masked tablet, rapid-disintegrating tablet and tube-compatible presentations.
• Standard tablet excipients support low-cost generic manufacture but provide little defensible differentiation.
• Premium value requires a measurable administration benefit, such as accurate liquid dosing, no-water use or improved feeding-tube compatibility.
• Rilutek has no biosimilar risk because riluzole is a small molecule.
• Formulation, manufacturing and device patents can remain commercially relevant even after original compound protection expires.
• Regulatory value depends on bioequivalence, food-effect control, stability, taste, preservative performance and dose uniformity.
• The most attractive licensing targets are excipient and delivery platforms with applicability beyond riluzole.

FAQs

Can Rilutek tablets be crushed and administered through a feeding tube?

Administration through a feeding tube should be supported by product-specific compatibility and dose-recovery data. A dedicated suspension or tube-compatible formulation offers a stronger regulatory and commercial position than informal tablet manipulation.

Which excipient is most important for a generic riluzole suspension?

No single excipient controls performance. The critical system is the combination of suspending polymer, wetting agent, buffer, preservative, sweetener and flavor, supported by particle-size control and validated redispersibility.

Does a new Rilutek excipient combination create patent protection?

A new combination can support patent claims if it produces a novel and non-obvious composition or measurable technical effect. Routine substitution of common excipients usually provides weak protection.

Is riluzole suitable for an orally disintegrating tablet?

Yes, but bitterness, dose loading and mechanical strength are central development issues. A successful product would likely require both rapid disintegration and a dedicated taste-masking approach.

What is the best commercial entry point for a new Rilutek formulation?

A lower-cost oral suspension or a feeding-tube-compatible product offers the clearest unmet administration need. An oral film may provide stronger differentiation but requires greater manufacturing and packaging investment.

References

1. U.S. Food and Drug Administration. (2023). Rilutek (riluzole) tablets: Prescribing information.
2. U.S. Food and Drug Administration. (2018). Tiglutik (riluzole) oral suspension: Prescribing information.
3. U.S. Food and Drug Administration. (2020). Exservan (riluzole) oral film: Prescribing information.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
5. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database.
6. U.S. Food and Drug Administration. (2024). Changes to an approved NDA or ANDA: Scale-up and postapproval changes, SUPAC guidance.